|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: COX6C |
Gene summary for COX6C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | COX6C | Gene ID | 1345 |
| Gene name | cytochrome c oxidase subunit 6C | |
| Gene Alias | COX6C | |
| Cytomap | 8q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | A0A024R9B7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1345 | COX6C | GSM4909280 | Human | Breast | Precancer | 2.69e-06 | -7.59e-01 | 0.0305 |
| 1345 | COX6C | GSM4909281 | Human | Breast | IDC | 2.02e-137 | 8.78e-01 | 0.21 |
| 1345 | COX6C | GSM4909282 | Human | Breast | IDC | 7.16e-12 | 3.14e-01 | -0.0288 |
| 1345 | COX6C | GSM4909286 | Human | Breast | IDC | 3.17e-29 | 4.44e-01 | 0.1081 |
| 1345 | COX6C | GSM4909287 | Human | Breast | IDC | 5.15e-80 | 6.59e-01 | 0.2057 |
| 1345 | COX6C | GSM4909288 | Human | Breast | IDC | 1.96e-04 | 1.66e-01 | 0.0988 |
| 1345 | COX6C | GSM4909289 | Human | Breast | IDC | 2.07e-20 | 6.67e-01 | 0.1064 |
| 1345 | COX6C | GSM4909290 | Human | Breast | IDC | 2.12e-87 | 7.67e-01 | 0.2096 |
| 1345 | COX6C | GSM4909291 | Human | Breast | IDC | 3.99e-09 | 3.07e-01 | 0.1753 |
| 1345 | COX6C | GSM4909293 | Human | Breast | IDC | 2.78e-12 | 2.67e-01 | 0.1581 |
| 1345 | COX6C | GSM4909294 | Human | Breast | IDC | 1.32e-49 | 3.94e-01 | 0.2022 |
| 1345 | COX6C | GSM4909295 | Human | Breast | IDC | 9.55e-08 | 2.49e-01 | 0.0898 |
| 1345 | COX6C | GSM4909296 | Human | Breast | IDC | 4.19e-29 | 3.10e-01 | 0.1524 |
| 1345 | COX6C | GSM4909297 | Human | Breast | IDC | 4.05e-107 | 9.49e-01 | 0.1517 |
| 1345 | COX6C | GSM4909298 | Human | Breast | IDC | 6.45e-11 | 2.87e-01 | 0.1551 |
| 1345 | COX6C | GSM4909301 | Human | Breast | IDC | 2.85e-147 | 1.06e+00 | 0.1577 |
| 1345 | COX6C | GSM4909302 | Human | Breast | IDC | 5.38e-50 | 4.83e-01 | 0.1545 |
| 1345 | COX6C | GSM4909303 | Human | Breast | IDC | 4.97e-12 | 3.91e-01 | 0.0438 |
| 1345 | COX6C | GSM4909304 | Human | Breast | IDC | 1.53e-81 | 6.77e-01 | 0.1636 |
| 1345 | COX6C | GSM4909305 | Human | Breast | IDC | 3.10e-06 | 2.95e-01 | 0.0436 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00427759 | Cervix | CC | mitochondrial ATP synthesis coupled electron transport | 38/2311 | 95/18723 | 8.45e-12 | 2.66e-09 | 38 |
| GO:00196469 | Cervix | CC | aerobic electron transport chain | 36/2311 | 87/18723 | 9.15e-12 | 2.74e-09 | 36 |
| GO:00229049 | Cervix | CC | respiratory electron transport chain | 42/2311 | 114/18723 | 1.67e-11 | 4.77e-09 | 42 |
| GO:00453339 | Cervix | CC | cellular respiration | 66/2311 | 230/18723 | 2.07e-11 | 5.39e-09 | 66 |
| GO:00229009 | Cervix | CC | electron transport chain | 53/2311 | 175/18723 | 2.23e-10 | 3.43e-08 | 53 |
| GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
| GO:00159809 | Cervix | CC | energy derivation by oxidation of organic compounds | 74/2311 | 318/18723 | 3.83e-08 | 2.53e-06 | 74 |
| GO:00061239 | Cervix | CC | mitochondrial electron transport, cytochrome c to oxygen | 9/2311 | 21/18723 | 4.77e-04 | 4.69e-03 | 9 |
| GO:004603415 | Cervix | HSIL_HPV | ATP metabolic process | 36/737 | 277/18723 | 3.06e-10 | 7.02e-08 | 36 |
| GO:000611914 | Cervix | HSIL_HPV | oxidative phosphorylation | 23/737 | 141/18723 | 6.76e-09 | 8.80e-07 | 23 |
| GO:001964614 | Cervix | HSIL_HPV | aerobic electron transport chain | 15/737 | 87/18723 | 1.38e-06 | 6.26e-05 | 15 |
| GO:000906014 | Cervix | HSIL_HPV | aerobic respiration | 23/737 | 189/18723 | 1.59e-06 | 6.90e-05 | 23 |
| GO:004277314 | Cervix | HSIL_HPV | ATP synthesis coupled electron transport | 15/737 | 95/18723 | 4.31e-06 | 1.70e-04 | 15 |
| GO:004277514 | Cervix | HSIL_HPV | mitochondrial ATP synthesis coupled electron transport | 15/737 | 95/18723 | 4.31e-06 | 1.70e-04 | 15 |
| GO:002290414 | Cervix | HSIL_HPV | respiratory electron transport chain | 15/737 | 114/18723 | 4.08e-05 | 1.08e-03 | 15 |
| GO:004533314 | Cervix | HSIL_HPV | cellular respiration | 23/737 | 230/18723 | 4.13e-05 | 1.09e-03 | 23 |
| GO:000612313 | Cervix | HSIL_HPV | mitochondrial electron transport, cytochrome c to oxygen | 6/737 | 21/18723 | 1.19e-04 | 2.42e-03 | 6 |
| GO:002290014 | Cervix | HSIL_HPV | electron transport chain | 18/737 | 175/18723 | 1.93e-04 | 3.56e-03 | 18 |
| GO:001598014 | Cervix | HSIL_HPV | energy derivation by oxidation of organic compounds | 24/737 | 318/18723 | 1.84e-03 | 1.96e-02 | 24 |
| GO:000609114 | Cervix | HSIL_HPV | generation of precursor metabolites and energy | 32/737 | 490/18723 | 3.69e-03 | 3.27e-02 | 32 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0493216 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
| hsa0426016 | Breast | Precancer | Cardiac muscle contraction | 22/684 | 87/8465 | 9.72e-07 | 1.62e-05 | 1.24e-05 | 22 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| COX6C | SNV | Missense_Mutation | c.169G>T | p.Asp57Tyr | p.D57Y | P09669 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A08X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | PD | |
| COX6C | SNV | Missense_Mutation | c.181N>T | p.Asp61Tyr | p.D61Y | P09669 | protein_coding | deleterious(0.01) | benign(0.33) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| COX6C | SNV | Missense_Mutation | rs746221706 | c.119N>A | p.Arg40His | p.R40H | P09669 | protein_coding | tolerated(0.14) | benign(0.105) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| COX6C | SNV | Missense_Mutation | rs201229067 | c.59G>A | p.Arg20Gln | p.R20Q | P09669 | protein_coding | tolerated(0.19) | benign(0.079) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| COX6C | SNV | Missense_Mutation | rs376349848 | c.148N>A | p.Ala50Thr | p.A50T | P09669 | protein_coding | tolerated(0.07) | benign(0.182) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| COX6C | SNV | Missense_Mutation | rs766823907 | c.118N>T | p.Arg40Cys | p.R40C | P09669 | protein_coding | tolerated(0.09) | benign(0.155) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| COX6C | SNV | Missense_Mutation | novel | c.163N>C | p.Asn55His | p.N55H | P09669 | protein_coding | deleterious(0.04) | probably_damaging(0.985) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| COX6C | SNV | Missense_Mutation | rs201229067 | c.59N>A | p.Arg20Gln | p.R20Q | P09669 | protein_coding | tolerated(0.19) | benign(0.079) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| COX6C | SNV | Missense_Mutation | c.181N>T | p.Asp61Tyr | p.D61Y | P09669 | protein_coding | deleterious(0.01) | benign(0.33) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| COX6C | SNV | Missense_Mutation | novel | c.151N>T | p.Asp51Tyr | p.D51Y | P09669 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |